[go: up one dir, main page]

NO20041485L - Farmasoytisk formulering omfattende (R)-bicalutamid - Google Patents

Farmasoytisk formulering omfattende (R)-bicalutamid

Info

Publication number
NO20041485L
NO20041485L NO20041485A NO20041485A NO20041485L NO 20041485 L NO20041485 L NO 20041485L NO 20041485 A NO20041485 A NO 20041485A NO 20041485 A NO20041485 A NO 20041485A NO 20041485 L NO20041485 L NO 20041485L
Authority
NO
Norway
Prior art keywords
bicalutamide
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
NO20041485A
Other languages
English (en)
Inventor
Nicola Frances Bateman
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20041485L publication Critical patent/NO20041485L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20041485A 2001-10-15 2004-04-13 Farmasoytisk formulering omfattende (R)-bicalutamid NO20041485L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation
PCT/GB2002/004621 WO2003032950A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide

Publications (1)

Publication Number Publication Date
NO20041485L true NO20041485L (no) 2004-04-13

Family

ID=20285650

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041485A NO20041485L (no) 2001-10-15 2004-04-13 Farmasoytisk formulering omfattende (R)-bicalutamid

Country Status (19)

Country Link
US (1) US20060058381A1 (no)
EP (1) EP1439823A1 (no)
JP (1) JP3639587B2 (no)
KR (1) KR20050035163A (no)
CN (1) CN1571658A (no)
AR (1) AR036877A1 (no)
BR (1) BR0213248A (no)
CA (1) CA2462219A1 (no)
CO (1) CO5580755A2 (no)
HU (1) HUP0401369A3 (no)
IL (1) IL161306A0 (no)
IS (1) IS7219A (no)
MX (1) MXPA04003520A (no)
NO (1) NO20041485L (no)
PL (1) PL368226A1 (no)
RU (1) RU2004115023A (no)
SE (1) SE0103424D0 (no)
WO (1) WO2003032950A1 (no)
ZA (1) ZA200402729B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030077042A (ko) * 2001-02-27 2003-09-29 아스트라제네카 아베 비칼루타마이드를 포함하는 약학 제제
BRPI0507007A (pt) 2004-01-20 2007-06-05 Novartis Ag formulação e processo de compressão direta
CN101128195A (zh) * 2005-02-23 2008-02-20 阿斯利康(瑞典)有限公司 用于递送增加的稳态血浆水平的比卡鲁胺
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
CA2761389A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
US20140288037A1 (en) * 2011-07-18 2014-09-25 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
US20140179749A1 (en) 2012-09-11 2014-06-26 Bend Research Formulations of enzalutamide
AU2014236135A1 (en) 2013-03-14 2015-09-10 Thomas Jefferson University Androgen receptor down-regulating agents and uses thereof
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
KR102387089B1 (ko) 2014-12-05 2022-04-14 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물
KR102348320B1 (ko) * 2014-12-05 2022-01-10 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629237A (en) * 1968-09-12 1971-12-21 Shinetsu Chemical Co Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
DE3372965D1 (en) * 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
JP2527107B2 (ja) * 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
AU1687395A (en) * 1994-01-21 1995-08-08 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
KR20030077042A (ko) * 2001-02-27 2003-09-29 아스트라제네카 아베 비칼루타마이드를 포함하는 약학 제제
JP2004525164A (ja) * 2001-04-02 2004-08-19 アストラゼネカ アクチボラグ 4−シアノ−トリフルオロ−3−(4−フルオロフェニルスルホニル)−2−ヒドロキシ−2−メチルプロピオノ−m−トルイジドとPVPを含む固体医薬組成物

Also Published As

Publication number Publication date
HUP0401369A3 (en) 2006-05-29
EP1439823A1 (en) 2004-07-28
JP3639587B2 (ja) 2005-04-20
HUP0401369A2 (hu) 2004-11-29
ZA200402729B (en) 2005-01-13
MXPA04003520A (es) 2004-07-23
AR036877A1 (es) 2004-10-13
KR20050035163A (ko) 2005-04-15
CO5580755A2 (es) 2005-11-30
CA2462219A1 (en) 2003-04-24
PL368226A1 (en) 2005-03-21
BR0213248A (pt) 2004-09-28
IS7219A (is) 2004-04-14
CN1571658A (zh) 2005-01-26
WO2003032950A1 (en) 2003-04-24
IL161306A0 (en) 2004-09-27
JP2004521963A (ja) 2004-07-22
US20060058381A1 (en) 2006-03-16
RU2004115023A (ru) 2005-04-10
SE0103424D0 (sv) 2001-10-15

Similar Documents

Publication Publication Date Title
NO20033384D0 (no) Farmasöytisk formulering
NO20033785D0 (no) Farmasöytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
ITTO20010008A0 (it) Formulazione farmaceutica
FI20011478L (fi) Farmaseuttinen koostumus
NO20035627D0 (no) Farmasöytisk formulering
IS7051A (is) Lyfjasamsetningar
FI20022128A0 (fi) Farmaseuttinen koostumus
NO20042502L (no) Farmasoytisk formulering omfattende bicalutamid
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DK1429753T3 (da) Farmaceutisk sammensætning omfattende gamma-butyrobetain
NO20015534D0 (no) Farmasöytisk blandeapparat
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DE10107261B4 (de) Pharmazeutische Zusammensetzung
NO20041236L (no) Farmasoytisk formulering
SE0102069D0 (sv) Pharmaceutical formulation
SE0101171D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
EP1413314A4 (en) MEDICAL COMPOSITIONS
GB0104749D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application